[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532528":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants",null,"Participants who have received maribavir treatment for the approved indication after marketing authorization (de novo participants) and before marketing authorization (legacy participants) under expanded access type of program or compassionate use in the real-world setting. Data will be collected prospectively and\u002For retrospectively from the medical records during this observational period of 16 weeks.",[13],"Other: No Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No Intervention","This is non-interventional study.",[9],[21],{"name":22,"affiliation":5,"role":23},"Study Director","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Takeda Contact","CONTACT","+1-877-825-3327","medinfoUS@takeda.com",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":10,"geoPoint":10,"contacts":38},"IC Projects","RECRUITING","City of Buenos Aires","C11119ACN","Argentina","AR",[39,42],{"name":10,"role":27,"phone":40,"phoneExt":10,"email":41},"(54911)-4076-7468","rbozzo@icprojects.com.ar",{"name":43,"role":44,"phone":10,"phoneExt":10,"email":10},"Raul Bozzo","PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100532528","a-study-of-maribavir-in-adults-and-children-with-post-transplant-cytomegalovirus-cmv-infection-in-argentina-100532528",false,"NCT06213974","A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina","Post Authorization Study to Monitor Efficacy, Effectiveness, and Safety of Maribavir (LIVTENCITY®) in Patients With Post-transplant Cytomegalovirus (CMV) Infection in Argentina","Inclusion Criteria:\n\n* Adult participants (18 years or older) and pediatric participants (12 years of age and older and weighing at least 35 kilogram \\[kg\\]) with post-transplant CMV infection\u002Fdisease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in the real-world setting of common clinical practice in Argentina.\n* Have received at least one dose of maribavir according to approved indications.\n* Have signed the mandatory informed consent\u002Fassent that has been agreed with national regulatory authorities (ANMAT) as applicable.\n\nExclusion Criteria\n\n\\- There are no specific exclusion criteria.","ALL","12 Years",{"count":57,"type":58},10,"ESTIMATED","OBSERVATIONAL","The main aim of this study is to learn about the safety of Maribavir in adults and children with post-transplant CMV infection in routine clinical practice in Argentina.\n\nThe other aim is to study the effectiveness of the treatment with Maribavir in routine clinical practice in Argentina.\n\nParticipants will be treated by their doctors according to normal medical practice. Study data will be collected either from information already available in the medical records or during study conduct.",[62],"Cytomegalovirus (CMV)","2026-06-02",{"date":65,"type":66},"2026-06-04","ACTUAL",{"date":68,"type":66},"2024-09-03",{"date":70,"type":58},"2026-07-31",{"name":5,"class":6},1]